AU2001280764A1 - Drug delivery system for enhanced bioavailability of hydrophobic active ingredients - Google Patents

Drug delivery system for enhanced bioavailability of hydrophobic active ingredients

Info

Publication number: AU2001280764A1
Authority: AU; Australia
Prior art keywords: delivery system; drug delivery; active ingredients; hydrophobic active; enhanced bioavailability
Prior art date: 2000-08-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001280764A

Inventor

Joshua Gatts

Charles Hsiao

Ching-Ling Teng

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Impax Laboratories LLC

Original Assignee

Impax Laboratories LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-09

Filing date

2001-07-26

Publication date

2002-02-18

2001-07-26 Application filed by Impax Laboratories LLC filed Critical Impax Laboratories LLC

2002-02-18 Publication of AU2001280764A1 publication Critical patent/AU2001280764A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU2001280764A 2000-08-09 2001-07-26 Drug delivery system for enhanced bioavailability of hydrophobic active ingredients Abandoned AU2001280764A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09635234		2000-08-09
US09/635,234 US6531158B1 (en)	2000-08-09	2000-08-09	Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
PCT/US2001/023401 WO2002011699A1 (en)	2000-08-09	2001-07-26	Drug delivery system for enhanced bioavailability of hydrophobic active ingredients

Publications (1)

Publication Number	Publication Date
AU2001280764A1 true AU2001280764A1 (en)	2002-02-18

Family

ID=24546994

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001280764A Abandoned AU2001280764A1 (en)	2000-08-09	2001-07-26	Drug delivery system for enhanced bioavailability of hydrophobic active ingredients

Country Status (4)

Country	Link
US (2)	US6531158B1 (en)
AU (1)	AU2001280764A1 (en)
TW (1)	TWI285116B (en)
WO (1)	WO2002011699A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL130602A0 (en)	1999-06-22	2000-06-01	Dexcel Ltd	Stable benzimidazole formulation
KR20030076715A (en) *	2001-03-01	2003-09-26	그레랑 파마수티컬 가부시키가이샤	Fenofibrate containing composition
WO2003082247A2 (en) *	2002-03-26	2003-10-09	Teva Pharmaceutical Industries Ltd.	Drug microparticles
AU2003263480A1 (en) *	2002-09-24	2004-04-19	Ranbaxy Laboratories Limited	Oral pharmaceutical compositions of fenofibrate having high bioavailability
CN100473378C (en) *	2002-12-17	2009-04-01	阿伯特有限及两合公司	Formulations comprising fenofibric acid, physiologically acceptable salts or derivatives thereof
EP1829541A1 (en) *	2002-12-17	2007-09-05	Abbott GmbH & Co. KG	Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
BE1015641A4 (en) *	2003-05-26	2005-07-05	Mariani Jean Paul	Micronization 70.
EP1559419A1 (en) *	2004-01-23	2005-08-03	Fournier Laboratories Ireland Limited	Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP5449780B2 (en)	2006-01-20	2014-03-19	オキュラスイノヴェイティヴサイエンシズ、インコーポレイテッド	Method for treating or preventing inflammation and hypersensitivity using redox potential aqueous solution
CA2644905A1 (en) *	2006-03-06	2007-09-13	Teva Pharmaceutical Industries Ltd.	Ezetimibe compositions
SI2029110T1 (en) *	2006-06-06	2012-01-31	Tibotec Pharm Ltd	Process for preparing spray dried formulations of tmc125
RU2009102262A (en) *	2006-06-26	2010-08-10	Мьючуал Фармасьютикал Компани, Инк. (Us)	COMPOSITIONS OF ACTIVE AGENT, WAYS OF THEIR OBTAINING AND WAYS OF APPLICATION
CA2673419A1 (en) *	2006-12-21	2008-06-26	Alphapharm Pty Ltd	Pharmaceutical composition
WO2008104846A2 (en) *	2007-02-26	2008-09-04	Wockhardt Research Centre	Pharmaceutical compositions of fenofibrate
US9180110B2 (en)	2007-02-26	2015-11-10	Wockhardt Ltd.	Pharmaceutical compositions of fenofibrate
WO2009042114A2 (en)	2007-09-21	2009-04-02	The Johns Hopkins University	Phenazine derivatives and uses thereof
JP2012500221A (en)	2008-08-15	2012-01-05	ディポメド，インコーポレイティド	Gastric retentive pharmaceutical composition for treatment and prevention of CNS disorders
US20100159010A1 (en) *	2008-12-24	2010-06-24	Mutual Pharmaceutical Company, Inc.	Active Agent Formulations, Methods of Making, and Methods of Use
WO2010078429A1 (en) *	2008-12-30	2010-07-08	Impax Laboratories, Inc.	Pharmaceutical dosage forms and methods of manufacturing same
FR2943539B1 (en) *	2009-03-31	2011-07-22	Ethypharm Sa	PHARMACEUTICAL COMPOSITION COMPRISING A IMMUNOSUPPRESSIVE MACROLIDE OF THE LIMUS FAMILY.
MX386504B (en)	2009-06-15	2025-03-19	Sanfer Farma S A P I De C V	SOLUTION CONTAINING HYPOCHLOROUS ACID AND METHODS FOR USING SAME.
KR101202994B1 (en) *	2010-04-12	2012-11-21	한미사이언스 주식회사	Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
WO2014091318A1 (en)	2012-12-11	2014-06-19	Lupin Atlantis Holdings, S.A.	Reduced dose pharmaceutical compositions of fenofibrate
EP3609474A4 (en) *	2017-04-13	2021-01-27	Pharmako Biotechnologies PTY Limited	DISTRIBUTION SYSTEM FOR CHEMICALS DISPERSIBLE IN COLD WATER

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3639637A (en)	1968-04-23	1972-02-01	Richardson Merrell Inc	Water dispersible diethylstilbestrol compositions
US4013785A (en)	1975-03-21	1977-03-22	Bristol-Myers Company	Apap tablet containing fumed silica and process for manufacturing same
GB1579818A (en)	1977-06-07	1980-11-26	Yamanouchi Pharma Co Ltd	Nifedipine-containing solid preparation composition
US4153678A (en) *	1978-07-17	1979-05-08	American Cyanamid Company	Levamisole effervescent tablets
US4344934A (en) *	1978-11-20	1982-08-17	American Home Products Corporation	Therapeutic compositions with enhanced bioavailability
FR2494112B1 (en)	1980-11-19	1986-01-10	Laruelle Claude
DE3107933A1 (en)	1981-03-02	1982-09-16	Cassella Ag, 6000 Frankfurt	SUBSTITUTED 3-AMINO-SYDNONIMINE, METHOD FOR THE PRODUCTION AND USE THEREOF
DE3247118A1 (en)	1982-12-20	1984-06-20	Cassella Ag, 6000 Frankfurt	NEW SUBSTITUTED 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
FR2557459B1 (en)	1984-01-02	1986-05-30	Lhd Lab Hygiene Dietetique	POLYCAPROLACTONE-BASED INERT MATRIX FOR ORAL ADMINISTRATION OF A MEDICAMENT, AND METHOD FOR PREPARING THE GALENIC FORM COMPRISING THE SAME
US4721709A (en)	1984-07-26	1988-01-26	Pyare Seth	Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
EP0179583A1 (en)	1984-10-04	1986-04-30	Merck & Co. Inc.	A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
WO1987000428A1 (en)	1985-07-24	1987-01-29	Pyare Seth	Oxazepam containing pharmaceutical composition
US4716033A (en)	1986-03-27	1987-12-29	Warner-Lambert Company	Medicament adsorbates with surfactant and their preparation
FR2602423B1 (en)	1986-08-08	1989-05-05	Ethypharm Sa	PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS
US4859703A (en)	1987-06-15	1989-08-22	Warner-Lambert Company	Lipid regulating compositions
FR2627696B1 (en) *	1988-02-26	1991-09-13	Fournier Innovation Synergie	NEW GALENIC FORM OF FENOFIBRATE
SE8803935L (en) *	1988-10-31	1990-05-01	Kabivitrum Ab	LAEKEMEDELSKOMPOSITION
US5228400A (en) *	1991-07-30	1993-07-20	Luke William J	Planting tool
TW355683B (en) *	1994-02-17	1999-04-11	Janssen Pharmaceutica Nv	Composition containing micronized nebivolol
US5948438A (en)	1995-01-09	1999-09-07	Edward Mendell Co., Inc.	Pharmaceutical formulations having improved disintegration and/or absorptivity
US5545628A (en) *	1995-01-10	1996-08-13	Galephar P.R. Inc.	Pharmaceutical composition containing fenofibrate
FR2737121B1 (en)	1995-07-27	1997-10-03	Cl Pharma	NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS
US5769934A (en)	1997-01-15	1998-06-23	Fmc Corporation	Method for producing microcrystalline cellulose
FR2758459B1 (en) *	1997-01-17	1999-05-07	Pharma Pass	FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
CA2214895C (en) *	1997-09-19	1999-04-20	Bernard Charles Sherman	Improved pharmaceutical composition comprising fenofibrate
FR2774591B1 (en) *	1998-02-12	2000-05-05	Lipha	PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
AP1224A (en) *	1998-03-19	2003-11-14	Bristol Myers Squibb Co	Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2270306C (en) *	1999-04-27	2000-09-26	Bernard Charles Sherman	Pharmaceutical compositions comprising co-micronized fenofibrate

2000
- 2000-08-09 US US09/635,234 patent/US6531158B1/en not_active Expired - Fee Related
2001
- 2001-07-26 AU AU2001280764A patent/AU2001280764A1/en not_active Abandoned
- 2001-07-26 WO PCT/US2001/023401 patent/WO2002011699A1/en not_active Ceased
- 2001-08-01 TW TW090118724A patent/TWI285116B/en not_active IP Right Cessation
2002
- 2002-11-21 US US10/300,808 patent/US20030138496A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030138496A1 (en)	2003-07-24
WO2002011699A1 (en)	2002-02-14
TWI285116B (en)	2007-08-11
US6531158B1 (en)	2003-03-11

Publication	Publication Date	Title
AU2001280764A1 (en)	2002-02-18	Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
AU2002216701A1 (en)	2002-05-27	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU4996300A (en)	2000-11-21	Method of electroporation-enhanced delivery of active agents
AU4334700A (en)	2000-10-23	Pharmaceutical dosage form for pulsatile delivery of methylphenidate
EP1246608A4 (en)	2005-05-18	Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
AU2001283563A1 (en)	2002-02-25	Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AU2879100A (en)	2000-08-29	Formulation and system for intra-oral delivery of pharmaceutical agents
AU6168699A (en)	2000-10-09	Non-compliant system for delivery of implant material
EP1392241A4 (en)	2006-01-25	System for osmotic delivery of pharmaceutically active agents
AU2001234114A1 (en)	2001-09-03	Drugs containing combined active ingredients
AU2513900A (en)	2000-08-07	Drug dosage unit for buccal administration of steroidal active agents
AU2002343555A1 (en)	2003-05-26	Eutectic-based self-nanoemulsified drug delivery system
SI1608362T1 (en)	2007-12-31	Stabilized pharmaceutical preparation comprising an amorphous active substance
AU2001277171A1 (en)	2002-02-05	Catheter for target specific drug delivery
AU2001238346A1 (en)	2001-08-27	Modification of biopolymers for improved drug delivery
AU2003301444A1 (en)	2004-05-04	System for delivery of active substances
AU6386801A (en)	2001-11-12	System for the release of active ingredients
AU2001227030A1 (en)	2002-06-03	Pharmaceutical composition for controlled release of an active ingredient
IL154268A0 (en)	2003-09-17	Improved solid pharmaceutical dosage formulation of hydrophobic drugs
AU3669700A (en)	2000-10-23	4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU2002332836A1 (en)	2003-03-18	Stabilizing catheter for protein drug delivery
AU2001260089A1 (en)	2001-12-03	Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2002218271A1 (en)	2002-05-21	Multilayered supporting construction for plaster systems containing an active ingredient
AU1141101A (en)	2001-04-30	Pharmaceutical aerosol formulations comprising s-salmeterol
AU2002212863A1 (en)	2002-05-15	Stable pharmaceutical form of an anticancer drug